Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab

Int J Hematol. 2009 Apr;89(3):400-402. doi: 10.1007/s12185-009-0295-4. Epub 2009 Mar 31.

Authors

Takashi Sonoki¹, Yaqiong Li², Setsuko Miyanishi³, Hirokazu Nakamine⁴, Nobuyoshi Hanaoka⁵, Hiroshi Matsuoka⁵, Ichiro Mori², Hideki Nakakuma⁵

Affiliations

¹ Department of Hematology/Oncology, Wakayama Medical University, 811-1 Kimi-idera, Wakayama, 633-1611, Japan. sonoki@wakayama-med.ac.jp.
² 2nd Department of Pathology, Wakayama Medical University, Wakayama, Japan.
³ Tenri Institute of Medical Research, Nara, Japan.
⁴ Division of Pathology and Immunology, Kansai University of Health Sciences, Osaka, Japan.
⁵ Department of Hematology/Oncology, Wakayama Medical University, 811-1 Kimi-idera, Wakayama, 633-1611, Japan.

PMID: 19330555
DOI: 10.1007/s12185-009-0295-4

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 / genetics
Antigens, CD20 / immunology*
B-Lymphocytes / cytology*
B-Lymphocytes / immunology*
Cell Differentiation
Cell Line
Cell Separation / methods*
Female
Humans
Immunotherapy
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics
Lymphoma, Large B-Cell, Diffuse / immunology*
Lymphoma, Large B-Cell, Diffuse / pathology
Middle Aged
Rituximab
Tumor Cells, Cultured

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Rituximab